ITCC-070 Daratumumab
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia
Promotor Name : Janssen
Investigator Name :
Trial registered on clinicaltrial.gov : NCT03384654